Shortcut Navigation:

Observational Study Seeks Women with Metastatic HER2 Positive Breast Cancer

New registry created to monitor treatments and outcomes

Trial Starts: June 2012 Trial Ends: December 2020

Written By Nicole Katze, MA, Editor and Manager, Content Development
Reviewed By D. Lawrence Wickerham, MD

The new SystHERs (Systematic Therapies for HER2 positive Metastatic Breast Cancer Study) Registry seeks to enroll 1,000 people with HER2 positive metastatic breast cancer to analyze treatment patterns and outcomes.

About the Study

Observational cohort studies follow a group of people over a long period to look for common practices in treatment, risk factors or side effects that develop, and whether treatments work and for how long.

The SystHERs Registry aims to create a record of people with metastatic HER2 positive breast cancer to collect data on unique treatments used for the disease, as well as the cycle and order of treatments given.

Secondary outcomes include safety of treatments; progression-free survival, the length of time after starting treatment cancer does not grow; overall survival, the time from the start of treatment until death; post-progression survival, the time from cancer progression until death; and time-to-treatment failure, the length of time a treatment works effectively.

Genentech, the sponsor for this clinical trial, manufactures medicines used in metastatic HER2 positive breast cancer, including trastuzumab (Herceptin) and pertuzumab (Perjeta).

Who Is Eligible?

You may be eligible to participate if you:

  • Are 18 years old or older
  • Have HER2 positive metastatic breast cancer
  • Were diagnosed within the last six months

Study Locations

This study is being held in 95 locations throughout the United States. For a full listing of locations and local contact information, see trial NCT01615086 on, or the link below.

SystHERs Registry on